Expertise in
6
conditions

Dr. Atul K. Singhal

Rheumatology
1600 Republic Pkwy, Ste 200, 
Mesquite, TX 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
6
conditions
1600 Republic Pkwy, Ste 200, 
Mesquite, TX 

Overview

Atul Singhal is a Rheumatologist practicing medicine in Mesquite, Texas.

Dr. Singhal is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Rheumatoid Arthritis (RA), Psoriatic Arthritis, Arthritis, and Psoriasis.

He is actively involved in clinical research, co-authoring 13 peer reviewed articles and participating in 11 clinical trials. Dr. Singhal is currently accepting new patients.

Specialties

Rheumatology

Licenses

Internal Medicine in TX

Fellowships

University of Pennsylvania - Penn Dental Medicine (1995)

Hospital Affiliations

Texas Health Dallas

Languages Spoken

English
Hindi

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Southwest Rheumatology Research
1600 Republic Pkwy, Ste 200, Mesquite, TX 75150

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
Vagus Nerve Stimulation Using the SetPoint System for Moderate to Severe Rheumatoid Arthritis: The RESET-RA Study
Vagus Nerve Stimulation Using the SetPoint System for Moderate to Severe Rheumatoid Arthritis: The RESET-RA Study
Enrollment Status: Active_not_recruiting
Publish Date: April 14, 2026
Intervention Type: Procedure, Device, Drug
Study Drug: Conventional Synthetic DMARD
Study Phase: Phase 3
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of VIB1116 in Conventional Dendritic Cell (cDC) and Plasmacytoid Dendritic Cell (pDC)-Mediated Rheumatic Diseases
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of VIB1116 in Conventional Dendritic Cell (cDC) and Plasmacytoid Dendritic Cell (pDC)-Mediated Rheumatic Diseases
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: July 23, 2024
Intervention Type: Drug, Other
Study Drug: VIB7734
Study Phase: Phase 2
A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK-079 in Combination With Standard Background Therapy in Patients With Moderate to Severe Systemic Lupus Erythematosus
A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK-079 in Combination With Standard Background Therapy in Patients With Moderate to Severe Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: March 29, 2024
Intervention Type: Drug
Study Drug: TAK-079
Study Phase: Phase 1
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)
Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)
Enrollment Status: Completed
Publish Date: November 23, 2021
Intervention Type: Drug, Biological
Study Drug: Zostavax Herpes Zoster Vaccine
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 17, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

13 Total Publications

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo-Controlled Phase 3 Trials.
Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo-Controlled Phase 3 Trials.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: October 24, 2025
Similar Doctors
Expertise in
7
conditions
Expertise in
7
conditions
Referral may be required

Rheumatology Associates & Subsidiary

8144 Walnut Hill Ln Ste 800, 
Dallas, TX 
 (7.9 miles away)
214-540-0700
Languages Spoken:
English
See accepted insurances

Roy Fleischmann is a Rheumatologist practicing medicine in Dallas, Texas. Dr. Fleischmann is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Rheumatoid Arthritis (RA), Arthritis, Psoriatic Arthritis, and Psoriasis.

Expertise in
28
conditions
Expertise in
28
conditions
Referral may be required
Before you request

Rheumatology Associates

2021 N MacArthur Blvd, Ste 515, 
Irving, TX 
 (19.6 miles away)
214-540-0700
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Stanley Cohen is a Rheumatologist practicing medicine in Irving, Texas. Dr. Cohen is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Rheumatoid Arthritis (RA), Arthritis, Psoriasis, Psoriatic Arthritis, and Gastrostomy. Dr. Cohen is board certified in Rheumatology- American Board Of Internal Medicine, Rheumatology- American Board Of Internal Med/Rheumatology, Internal Medicine- American Board Of Internal Med, and Internal Medicine- American Board Of Internal Medicine. Dr. Cohen is currently accepting new patients.

Expertise in
29
conditions
Expertise in
29
conditions
Referral may be required
Before you request

Dallas County Hospital District

5200 Harry Hines Blvd, 
Dallas, TX 
 (12.4 miles away)
214-590-8000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bonnie Bermas is a Rheumatologist practicing medicine in Dallas, Texas. Dr. Bermas is highly rated in 29 conditions, according to our data. Her clinical expertise encompasses Lupus Nephritis, Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and Discoid Lupus Erythematosus (DLE).

Frequently Asked Questions about Dr. Atul K. Singhal

How do I make an appointment with Dr. Atul K. Singhal?

You can book an appointment with Dr. Atul K. Singhal by calling their office at 972-288-2600. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Atul K. Singhal a top-rated expert for Rheumatoid Arthritis (RA)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Atul K. Singhal is classified as an Advanced expert for Rheumatoid Arthritis (RA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Atul K. Singhal specialize in?

While Dr. Atul K. Singhal is a Rheumatology, they have specific expertise in Rheumatoid Arthritis (RA), Psoriatic Arthritis, and Arthritis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Atul K. Singhal participate in research or clinical trials?

Yes. Dr. Atul K. Singhal has published 13 articles and abstracts on conditions like Rheumatoid Arthritis (RA). You can view a list of Dr. Atul K. Singhal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Atul K. Singhal accept my insurance?

Dr. Atul K. Singhal accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 972-288-2600 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Singhal's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile